Concepedia

Author

Andrew Uzilov

Icahn School of Medicine at Mount SinaiORCID

Also Known As

A. Uzilov, Andrew Uzilov, Andrew V Uzilov, Andrew V. Uzilov, Uzilov, Andrew

98

Publications

2.9K

Citations

19

H-Index

40

Concepts

All Affiliations

Icahn School of Medicine at Mount SinaiSema4 (United States)Singapore General HospitalUniversity of California, BerkeleyMemorial Sloan Kettering Cancer Center
AU

About

Andrew Uzilov is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, bioinformatics, and functional genomics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

1.4K

2

Engineering

2

2

783

3

Health Sciences

2

2

330

4

Natural Sciences

2

2

22

5

Biostatistics

1

1

22

Andrew Uzilov

×

28

Publications

2.9K

Citations

19

H-Index

YearCitations

JBrowse: A next-generation genome browser

Mitchell E. Skinner, Andrew Uzilov, Lincoln Stein,

Genome Research

2009

761

FragSeq: transcriptome-wide RNA structure probing using high-throughput sequencing

Jason G. Underwood, Andrew Uzilov, Sol Katzman,

Nature Methods

2010

315

Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

Carla Montironi, Florian Castet, Philipp K. Haber,

Gut

2022

219

Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

Roser Pinyol, Sara Torrecilla, Huan Wang,

Journal of Hepatology

2021

217

Detection of non-coding RNAs on the basis of predicted secondary structure formation free energy change

Andrew Uzilov, Joshua M Keegan, David H. Mathews

BMC Bioinformatics

2006

208

Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers

Elena Pereira, Olga Camacho‐Vanegas, Sanya Anand,

PLoS ONE

2015

174

Genomic profiling reveals mutational landscape in parathyroid carcinomas

Chetanya Pandya, Andrew Uzilov, Justin Bellizzi,

JCI Insight

2017

118

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes

Matthew D. Galsky, Huan Wang, Noah M. Hahn,

European Urology

2017

113

A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer

Erdem Bangi, Celina Ang, Peter Smibert,

Science Advances

2019

100

Development and clinical application of an integrative genomic approach to personalized cancer therapy

Andrew Uzilov, Wei Ding, Marc Y. Fink,

Genome Medicine

2016

87

Page 1